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Objectives: The research was designed to examine the impact of the previous diagnoses of depression,
menopause status, vasomotor symptoms, and neuroticism on depressive symptoms among menopausal
women in Taiwan over a 30-month follow-up.
Materials and Methods: A community-based sample of 190 middle-aged women was enrolled. The
Menopausal Symptoms Scale, Neuroticism Extraversion Openness Five Factor InventorydChinese
version, and Ko's Depression Inventory were applied, and results were assessed. In addition, each woman
underwent a semistructured diagnostic interview with the Chinese version of the Modiﬁed Schedule of
Affective Disorders and SchizophreniadLifetime to obtain her lifetime psychiatric history. After 30
months, 111 participants completed follow-up questionnaires.
Results: Results of the hierarchical multiple regression analyses showed that depressive symptoms
during the menopause transition predicted depressive symptoms over 30 months. After controlling for
depressive symptoms during the menopause transition, the previous diagnoses of depression, meno-
pause status, and vasomotor symptoms could not predict depressive symptoms over 30 months, whereas
neuroticism still predicted depressive symptoms over 30 months.
Conclusion: The research suggested that neuroticism plays an important role in the persistence of
depression among climacteric women after 30 months.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Menopause is a major turning point in a woman's life in which
various physiological changes are experienced by all women who
reach 40e60 years of age. The gradual decrease in estrogen levels
that occurs during the menopause transition may cause women to
experience menopausal symptoms, which include aspects of so-
matic symptoms, sexual dysfunction, psychological symptoms, and, College of Humanities and
Road, Wufeng, Taichung 413,
bstetrics & Gynecology. Publishedvasomotor symptoms [1]. In addition, many women experience
depressive symptoms andmood disorders associated with the low-
estrogen phase of the menstrual cycle during menopause [2].
A potential association between depressive symptoms and
menopause transition has been postulated. Estrogen deﬁciency has
been suggested to predict depressive symptoms during the
climacteric duration [2]. Previous research on this topic has indi-
cated that menopause status is related to depressive symptoms
[1e3]. However, other studies have not supported the relationship
between menopausal status and depressive symptoms [2]. The
incompatible ﬁndings may be attributable to the lack of consider-
ation of confounding variables, such as surgical menopause, vaso-
motor symptoms, receiving hormone therapy (HT), previous
depression, and neuroticism.by Elsevier Taiwan LLC. All rights reserved.
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have been demonstrated to have higher rates of depression than
those who experience the natural menopause process [2e4].
Moreover, according to the symptom hypothesis, depressive
symptoms are explained by vasomotor symptoms associated with
changing estrogen levels [1,2]. In addition, women who experience
unstable and irregular estrogen patterns may choose to receive HT
in order to reduce menopausal symptoms. Receiving HT has also
been found to negatively correlate with menopause symptoms or
positively associate with depressive symptoms [1]. Premenstrual
dysphoric disorder (PMDD) [5,6], history of major depressive dis-
order (MDD) [7,8], and previous dysthymic disorder (PDD) [1,2,7]
have been shown to be highly associated with depressive symp-
toms in midlife. Furthermore, neuroticism has been shown to be
the best predictor of depressive symptoms in middle-aged women
[9]. Kuh et al [10] indicated that women in midlife with high levels
of neuroticism experiencemore psychological symptoms, including
depression or anxiety, irritability, tearfulness, and feelings of panic.
After controlling for confounding variables, such as receiving HT,
PMDD, history of MDD, PDD, and vasomotor symptoms, Lin et al
[11] found menopausal status as a predictor of depressive symp-
toms among climacteric women during the menopause transition,
and found this to be mediated by neuroticism. However, the study
adopted a cross-sectional design; therefore, no causal relationship
can be inferred clearly. The cross-sectional nature of the research
referenced above suggests a need for further examination of the
causal association among menopause status, neuroticism, and
depressive symptoms. In addition, participants who are experi-
encing depressive symptoms may overestimate or underestimate
the frequency or severity of the risks for depressive symptoms,
particularly if the assessment is retrospective in cross-sectional
research. Thus, the aim of the present prospective study was to
determine whether menopause status and neuroticism in meno-
pausal women, including those with pre-, peri-, and post-
menopausal statuses, predicted a higher occurrence of depressive
symptoms after 30 months in a community sample of midlife
women in Taiwan when controlling for depressive symptoms
measured during the menopause transition and confounding var-
iables such as receiving HT, PMDD, a history of MDD, PDD, and
vasomotor symptoms.
Materials and methods
Participants and procedures
The participants in the study were recruited from three districts
in Tainan City, Taiwan, using cluster sampling. We collaborated
with the three district ofﬁcials, who collected the relevantmaterials
for us, including informed consent, demographic variables
(menopause status, HT status, history of psychiatric treatment,
years of education, employment status), self-reported vasomotor
symptoms, depressive symptoms, and menopausal symptoms.
Initially, 316 women responded to our study.
We invited the respondents to complete the Neuroticism Ex-
traversion Openness Five Factor InventorydChinese version (NEO-
FFI-C); these women were then interviewed by trained research
associates using the Modiﬁed Schedule of Affective Disorders and
SchizophreniadLifetime (MSADS-L) to identify whether they had
suffered from PMDD or had a history of MDD or dysthymic disorder.
We excluded participants who were illiterate as well as those with
surgically induced menopause because of hysterectomy and/or
bilateral ovariectomy. Eventually, 130 women were excluded from
the study; the ﬁnal sample was 190 women, yielding a response
rate of 60.13%. During the menopause transition (time 1), we
further classiﬁed the participants into three groups according tomenopause status: pre-, peri-, and postmenopausal. After 30
months (time 2), 111 participants completed the follow-up ques-
tionnaires (follow-up rate, 35.13%). The demographic characteris-
tics and related variables for the follow-up and the nonfollowed
sample are presented in Table 1. There were no signiﬁcant differ-
ences among all variables between the follow-up and the non-
followed participants.
Measurements
Menopause status
We adapted the menopause status classiﬁcation deﬁned by the
World Health Organization [12]. In the study, participants self-
reported their menopause status according to the following deﬁ-
nitions: premenopausal was deﬁned as an unchanged menstrual
pattern; premenopausal was deﬁned as an irregular menstrual
pattern with at least one menstrual period in the preceding 12
months; and postmenopausal was deﬁned as experiencing amen-
orrhea for at least 1 year.
Menopausal Symptoms Scale
The Menopausal Symptoms Scale is a self-reported question-
naire that includes 25 items comprising four domains: somatic,
psychological, sexual, and vasomotor symptoms. Each item is rated
on a 4-point scale. Possible scores on the menopausal symptoms
range from 0 to 75, with higher scores indicating a greater severity
of menopausal symptoms. The internal consistency coefﬁcient was
0.84 for somatic symptoms, 0.83 for psychological symptoms, 0.87
for sexual symptoms, and 0.78 for vasomotor symptoms [11].
Neuroticism
The levels of neuroticism in the present study were assessed
using the NEO-FFI-C. The NEO-FFI-C is a Chinese modiﬁed version
of the Neuroticism Extraversion Openness Five Factor Inventory
[13], which is composed of 60 items and rated on a 5-point scale.
The coefﬁcient of Cronbach a for the ﬁve dimensions ranged from
0.44 to 0.65 [11].
Depression
The depression levels of participants over the previous week
were assessed using Ko's Depression Inventory (KDI), which was
developed by Ko [14] in 1989. The KDI, a self-reported depression
scale containing 26 items, has an internal consistency of 0.87 and
split-half reliability coefﬁcients averaging 0.87 [15]. A sensitivity of
85.53% and a speciﬁcity of 91.80% were obtained when it was
administered to screen for major depression [14]. A sensitivity of
84.62% and a speciﬁcity of 82.36% were obtained when it was
administered to screen for dysthymic disorder [16]. Moreover, a
highly positive correlation of 0.90 was revealed between the KDI
and Beck Depression Inventory among 276 psychiatric patients
[15], and a highly positive correlation was also found among the
KDI, Adult Suicidal Ideation QuestionnairedRevised, and depres-
sive symptoms to the Symptom Check List-90 Revised among col-
lege students [15,17,18].
Lifetime psychiatric history
All participants were personally interviewed by a research
associate for an initial evaluation. A more detailed subsequent
interview to determine the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Revision diagnoses was conducted using
the semistructured Chinese version of the MSADS-L, which was
based on the MSADS-L from Merikangas et al [19]. The interrater
reliability of the Chinese version of the MSADS-L has been inves-
tigated by comparing the diagnoses derived from independent
administration by psychiatrists and research associates. High
Table 1
Characteristics and related variables between the follow-up group and nonfollow-up group over 30 months of follow-up.
Variable Nonfollow-up (n ¼ 79) Follow-up (n ¼ 111) t/c2 p
Age, mean (SD) 49.96 (5.41) 50.13 (5.78) 0.20 0.69
Menopause status 3.14 0.52
Premenopausal 38 (48.10) 56 (50.45)
Perimenopausal 19 (24.05) 16 (14.41)
Postmenopausal 22 (33.66) 39 (35.14)
Had psychiatric treatment 0.26 0.12
Never 68 (96.20) 105 (94.59)
Ever 11 (3.80) 6 (5.41)
Had received HT 0.57 0.20
Never 68 (86.08) 91 (81.98)
Ever 11 (13.92) 20 (18.02)
Neuroticism, mean (SD) 28.91 (6.45) 28.87 (7.32) 0.04 0.87
Vasomotor symptoms (time 1), mean (SD)a 0.24 (4.72) 0.11 (3.53) 0.58 0.46
Depressive symptoms (time 1), mean (SD)b 9.80 (8.81) 10.25 (7.15) 0.39 0.57
Depressive symptoms (time 2), mean (SD)c d 9.57 (7.66) d d
Data are presented as n (%) unless otherwise indicated.
HT ¼ hormone therapy; SD ¼ standard deviation.
a Vasomotor symptoms during the menopause transition.
b Depressive symptoms during the menopause transition.
c Depressive symptoms over a 30-month follow-up.
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clinical diagnoses have been reported. The k values for schizo-
phrenia, affective disorder, anxiety disorder, and alcohol abuse and
dependence ranged from 0.71 to 1.0 between psychiatrists and
psychologists [20].
Statistical analysis
First, independent samples t test and Chi-square test were used
to identify statistically signiﬁcant differences between the follow-
up and nonfollow-up groups with respect to whole variables. Sec-
ond, to verify correlations between measures in the study,
Spearman and Pearson correlations were calculated. Third, a series
of hierarchical multiple regression analyses were conducted to
examine the role of neuroticism in the relationship between
menopause status and depressive symptoms over a 30-month
follow-up when controlling for depressive symptoms at time 1
and the possible confounders. All statistical analyses were per-
formed using PASW Statistics 18 for Windows. In the present study,
p < 0.05 was interpreted as statistically signiﬁcant.
Results
In Table 2, the correlation coefﬁcients are given for clinical
measures, neuroticism, vasomotor symptoms, depressiveTable 2
Correlational matrix of clinical measures, neuroticism, vasomotor symptoms, and depres
1 2 3
(1) PMDD 1
(2) History of MDD 0.13 1
(3) PDD 0.22* 0.03 1
(4) Menopause status 0.02 0.04 0.02
(5) Had received HT 0.00 0.06 0.05
(6) Neuroticism 0.24* 0.36** 0.05
(7) Vasomotor symptoms (time 1)a 0.22* 0.05 0.13
(8) Depressive symptoms (time 1)b 0.19* 0.26** 0.09
(9) Depressive symptoms (time 2)c 0.12 0.30** 0.13
*p < 0.05.
**p < 0.01.
HT ¼ hormone therapy; MDD ¼ major depressive disorder; PDD ¼ previous dysthymic
a Vasomotor symptoms during the menopause transition.
b Depressive symptoms during the menopause transition.
c Depressive symptoms over a 30-month follow-up.symptoms (time 1), and depressive symptoms (time 2). We found
PMDD, history of MDD, vasomotor symptoms, and neuroticism to
be positively associated with depressive symptoms (time 1).
Moreover, we found history of MDD, vasomotor symptoms, and
neuroticism to be positively associated with depressive symptoms
(time 2). There was a high correlation (0.72) in the relationship
between depressive symptoms (time 1) and depressive symptoms
(time 2). Furthermore, history of MDD was correlated with
neuroticism, depressive symptoms (time 1), and depressive
symptoms (time 2). Menopause status was positively associated
with receiving HT and vasomotor symptoms. Vasomotor symptoms
were positively correlated with PMDD, menopause status, neurot-
icism, depressive symptoms (time 1), and depressive symptoms
(time 2). Results of the hierarchical multiple regression analyses are
presented in Table 3. As presented in Table 3, depressive symptoms
(time 1) that predicted depressive symptoms (time 2) was entered
into step 1 as a control. In step 2, the impact of PMDD, history of
MDD, and PDD on depressive symptoms (time 2) were considered,
but were not found to be signiﬁcant. Depressive symptoms (time 1)
remained signiﬁcant in predicting depressive symptoms (time 2).
Furthermore, receiving HT, vasomotor symptoms, and menopause
status were added into step 3. The results showed that only
depressive symptoms (time 1) reached signiﬁcance in step 3. In
step 4, neuroticism was entered as a predictor of depressive
symptoms (time 2) and showed that depressive symptoms (time 1)sive symptoms (n ¼ 111).
4 5 6 7 8 9
1
0.46** 1
0.15 0.02 1
0.34** 0.07 0.48** 1
0.17 0.09 0.59** 0.44** 1
0.14 0.02 0.65** 0.36** 0.72** 1
disorder; PMDD ¼ premenstrual dysphoric disorder.
Table 3
Hierarchical regression analyses in predicting the depressive symptoms over a 30-
month follow-up (n ¼ 111).
Beta SE B p DR2
Step 1 0.515
Depressive symptoms (time 1)a 0.770 0.073 0.718 < 0.001*
Step 2
Depressive symptoms (time 1)a 0.536
PMDD 0.863 1.482 0.041 0.562
History of MDD 3.381 1.851 0.128 0.071
PDD 6.608 5.545 0.082 0.236
Step 3 0.540
Depressive symptoms (time 1)a 0.715 0.084 0.666 <0.001*
PMDD 0.922 1.525 0.044 0.547
History of MDD 3.407 1.882 0.129 0.073
PDD 6.106 5.621 0.076 0.280
Had received HT 0.086 0.178 0.040 0.630
Vasomotor symptoms (time 1)b 0.348 0.712 0.041 0.626
Menopause status 1.187 1.578 0.059 0.454
Step 4 0.605
Depressive symptoms (time 1)a 0.565 0.087 0.526 <0.001*
PMDD 1.531 1.428 0.073 0.286
History of MDD 1.261 1.832 0.048 0.493
PDD 7.035 5.240 0.088 0.182
Had received HT 0.110 0.173 0.051 0.526
Vasomotor symptoms (time 1)b 0.160 0.665 0.019 0.811
Menopause status 0.487 1.480 0.024 0.743
Neuroticism 0.369 0.091 0.351 <0.001*
*p < 0.001.
HT ¼ hormone therapy; MDD ¼ major depressive disorder; PDD ¼ previous dys-
thymic disorder; PMDD ¼ premenstrual dysphoric disorder; SE ¼ standard error.
a Depressive symptoms during the menopause transition.
b Vasomotor symptoms during the menopause transition.
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symptoms (time 1) and confounding variables, neuroticism
remained a predictor of depressive symptoms (time 2).Discussion
In our study, we found neuroticism to be signiﬁcantly associated
with depressive symptoms during the menopause transition.
Furthermore, after controlling for depressive symptoms during the
menopause transition and for other confounders, neuroticism still
predicted symptoms over 30 months, which suggests that neurot-
icism plays an important role in the persistence of depression
among climacteric women after 30 months. In the present study,
the positive relationship found between neuroticism and depres-
sive symptoms stands in accordance with the results of previous
research on this topic [9e11,21e24]. A possible explanation for the
casual relationship between neuroticism and depressive symptoms
is that people with high levels of neuroticism tend to experience
more distress. Climacteric women with high neurotic tendencies
are more likely to experience psychological pain and therefore may
be more predisposed to experience more depressive symptoms in
the future [11,23]. Second, the results are probably because
climacteric womenwith high neurotic tendencies aremore likely to
have false information about and negative attitudes toward estro-
gen deﬁcits, climacteric symptoms (hot ﬂashes, night sweats,
vaginal dryness, and dyspareunia), sexual dysfunction, aging, and
major life changes (retired from the workplace, empty nest, etc.)d
thus increasing and maintaining their tendency to experience
subjective and perceived stress, and therefore they may be more
predisposed to experience more depressive symptoms in the future
[1,22,24]. Third, neuroticism may presumably play an important
role in chronic depression. Individuals with high levels of neurot-
icism exhibit sensitivity to negative stimuli, resulting in a range ofnegative moods that are likely to predispose them to chronic
depression [25].
Our ﬁndings indicated that after controlling for depressive
symptoms during the menopause transition and confounding var-
iables, menopausal status was not a predictor of depressive
symptoms over 30 months. The results were in accordance with
previous ﬁndings [1,2,6,7,22]. One probable explanation for these
ﬁndings was the fact that the presence of both menopausal
symptoms and depressive symptoms during the menopausal
transition may illustrate a dissimilar phenomenon caused by
changes in the reproductive hormonal milieu, such as estrogen and/
or serotonin, to which some women are particularly impression-
able [7]. Thus, unexpected changes in neuromodulator function
and/or in reproductive hormone levels could contribute to the
constellation of depressive and menopausal symptoms seen in
some menopausal women. The second probable explanation for
these ﬁndings is that depressive symptoms during the menopause
transition may be associated with an earlier decline in ovarian
function, whereas depressive symptoms over 30 months may not.
Freeman [6] suggested that the greatest risks for new-onset
depression in midlife women may be in the transition to meno-
pause rather than in the postmenopausal years. Thus, menopause
status did not predict the depressive symptoms over 30 months
after controlling for depressive symptoms during the menopause
transition and for confounding variables. However, our ﬁndings
were not consistent with the conclusions of Lin et al [11]. A prob-
able explanation for this may be attributable to the longitudinal
design of the present study. In the cross-sectional results of Lin and
colleague [11], females who pointed out more menopausal dis-
tresses and vasomotor symptoms and who also had previous
depression expressed more depressive symptoms. Conversely, in-
dividuals who experienced more depressive symptoms were
shown to be more likely to indicate an increase in menopausal
reactions, additional vasomotor symptoms, or to have a history of
depression. Therefore, the relationships betweenmenopause status
and depressive symptoms need to be considered in prospective
research. In our prospective study, we found a causal relationship
between menopause status and depressive symptoms over 30
months.
In the present study, we found a history of MDD to be positively
associated with depressive symptoms during the menopause
transition as well as with depressive symptoms after 30 months.
These ﬁndings have been suggested from the results of previous
studies [1,2,6]. The probable explanation for the ﬁndings is that the
reproductive hormones are associated with mood among women
with a history of depression. Compared to women with no history
of depression, increased levels of Follicle-stimulating hormone
(FSH) and Luteinizing hormone (LH), decreased levels of inhibin b,
and increased variability of FSH and estradiol have been signiﬁ-
cantly correlated with the occurrence of depression among the
womenwho met the diagnostic criteria for depressive disorder [6].
However, after controlling for the impact of depressive symptoms
during the menopause transition on depressive symptoms after 30
months, the relationship between a history of MDD and depressive
symptoms after 30 months was not signiﬁcant. An explanation for
this is that the history of depressive disorder may have varying
impacts toward different stages of menopausal status. According to
Freeman's ﬁndings, it was suggested that a history of depression
may be associatedwith an earlier decline in ovarian function during
the menopause transition [6]. Thus, after the menopausal transi-
tion, women in midlife with a more stable status in ovarian func-
tion will experience less climacteric symptoms, and therefore will
not exhibit depression.
In our ﬁndings, vasomotor symptoms were positively correlated
with menopause status, depressive symptoms during the
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These ﬁndings stand in accordance with the results found in pre-
vious studies [1,2,6,7,22]. The probable reason for this is the domino
effect. During themenopause transition, vasomotor symptomsmay
disturb sleep, and sleep disruption has been found to cause nega-
tive moods [2,6]. However, after controlling for the impact of
depressive symptoms during the menopause transition on
depressive symptoms after 30 months, the relationship between
vasomotor symptoms and depressive symptoms after 30 months
was not signiﬁcant. We found that the impact of vasomotor
symptoms on depressive symptoms during the menopause tran-
sition was stronger as compared to the depressive symptoms after
30 months. In accordance with Freeman's [6] ﬁndings, a probable
explanation may be attributable to the impact of reproductive
hormones on menopausal transition, which suggested that vaso-
motor symptoms may be correlated with an earlier decline in
ovarian function during the menopause transition. After the
menopausal transition, women in midlife with a more stable status
in ovarian function will experience less climacteric symptoms or
will adjust to the vasomotor symptoms, and therefore will not
develop depression.
This study has several limitations. First, our sample size was
small (n ¼ 111); thus, caution is required when generalizing our
ﬁndings to large samples of middle-aged females undergoing
menopausal transition. Second, menopausal status was collected
from a pencil-and-paper self-report, which raises the possibility of
response bias. Recall bias and pressure to give socially desirable
answers might also be sources of error. In the future, we suggest
determining estrogen levels in prospective studies to investigate
the impact of menopause status on depressive mood in climacteric
women. Then, researchers can clearly evaluate the gradual decrease
in estrogen levels during and after the menopausal transition and
diminish recall bias in regard to reporting the actual menopausal
transition phase.
Despite the limitations discussed above, ﬁve strengths of this
study include: (1) the 30-month follow-up; (2) the use of randomly
selected, community-based participants from the general popula-
tion; (3) an age group covering the midlife years; (4) distinction
between natural and surgically caused menopause in women; and
(5) controlling for probable confounding variables correlated with
depressive symptoms, such as vasomotor symptoms, receiving HT,
previous diagnoses of depression, and depressive symptoms during
the menopausal transition phase. The present study revealed that
neuroticism plays an important role in the persistence of depres-
sion among climacteric women after 30 months. Thus, clinical ap-
proaches should assist climacteric women in Taiwan to build skills,
including adaptive emotion regulation strategies, mindfulness
[26,27], and yoga [28].
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